A Glimpse in the Future of Malignant Mesothelioma Treatment

Abstract

Malignant mesothelioma (MMe) is a rare neoplasm with few therapeutic options available. The landscape of effective therapy for this disease remained unchanged in the last two decades. Recently, however, the introduction of Immune Checkpoint Inhibitors (ICIs) led to small, but nevertheless, promising improvements. However, many efforts are still needed to radically improve the prognosis of MMe. In this review, we analyze all those therapeutic strategies for MMe that are still in a preclinical or early clinical phase of development. In particular, we focus on novel antiangiogenic drugs and their possible combination with immunotherapy. Furthermore, we describe also more complex strategies such as microRNA-loaded vectors, oncolytic viruses, and engineered lymphocytes.

Development of a prognostic nomogram for patients with malignant mesothelioma with bone metastasis

“…An increasing number of studies have focused on the treatment of MM, with options including surgery, radiotherapy, chemotherapy, and immunotherapy. Whether surgery can be performed is guided by the different age, performance status, and histological type of patients 17 . Pemetrexed and cisplatin combination chemotherapy are common treatment options, but the benefits of the regimen are limited, prognosis remains poor 18 .…”

Malignant Pleural Mesothelioma

“…Pezzoli et al's Special Article: Titled "A Glimpse in the Future of Malignant Mesothelioma Treatment," this article offers valuable insights into prospective developments in MPM treatment [81].…”